Sequence: LLRLLRWWWRLLRLL
| Experiment Id | EXP002480 |
|---|---|
| Paper | In Vivo Follow-Up of Gene Inhibition in Solid Tumors Using Peptide-Based Nanoparticles for siRNA Del |
| Peptide | WRAP5 |
| Delivery Success Class | no |
| In Vivo Flag | yes |
| Uptake Confirmed | yes |
| Label Confidence | medium |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | Peptide:siRNA molar ratio R = 20; peptide concentration not separately reported. |
| Rna Concentration | |
| Mixing Ratio | WRAP5:siRNA molar ratio R = 20; preincubated 30 min at room temperature in 5% glucose. |
| Formulation Format | peptide-based nanoparticle / non-covalent CPP:siRNA complex |
| Formulation Components | WRAP5:siRNA peptide-based nanoparticles formulated in 5% glucose; peptide:siRNA molar ratio R = 20; siFluc or siSCR; fluorescent siFluc-Alexa790/Cy3 included for imaging in some experiments. |
| Size Nm | 80.00 |
| Zeta Mv | 28.80 |
| Model Scope | in_vivo |
| Model Type | in vivo orthotopic brain tumor uptake/cell-tropism imaging |
| Cell Lines Or Primary Cells | U87-CMV/Fluc+ human glioblastoma cells |
| Animal Model | NSG mice bearing orthotopic U87-CMV/Fluc+ brain tumors |
| Administration Route | intratumoral/intracranial injection using stereotaxic frame |
| Output Type | in vivo uptake / tissue distribution imaging |
| Output Value | WRAP5:siFluc-Cy3 PBNs detected in tumor region 8 h after injection; histology showed PBN signal in CD44+ tumor cells and also GFAP+ glial cells and NeuN+ neurons. |
| Output Units | |
| Output Notes | This row records direct uptake/cell-tropism evidence in a separate orthotopic model. No functional reporter knockdown was quantified for this orthotopic experiment, so delivery_success_class remains 0. |
| Toxicity Notes | No toxicity assessment specific to this orthotopic uptake experiment was reported. |
| Curation Notes |